Correlation of 99mTc-DPD bone scintigraphy with histological amyloid load in patients with ATTR cardiac amyloidosis

References

• Eicher JC, Audia S, Damy T. Transthyretin cardiac amyloidosis. Rev Med Interne. 2020;41(10):673–683. doi: 10.1016/j.revmed.2020.07.002.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412. doi: 10.1161/CIRCULATIONAHA.116.021612.
   PubMed Web of Science ®Google Scholar
• Caobelli F, Braun M, Haaf P, et al. Quantitative (99m)Tc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: feasibility and correlation with visual scores. J Nucl Cardiol. 2020;27(5):1456–1463. doi: 10.1007/s12350-019-01893-8.
   PubMed Web of Science ®Google Scholar
• Escher F, Senoner M, Doerler J, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. 2020;109(1):78–88. doi: 10.1007/s00392-019-01490-2.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001;358(9275):24–29. doi: 10.1016/S0140-6736(00)05252-1.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122(1):78–84. doi: 10.1046/j.1365-2141.2003.04433.x.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–2371. doi: 10.1056/NEJMoa070265.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–4549. doi: 10.1200/JCO.2011.37.7614.
   PubMed Web of Science ®Google Scholar
• Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. doi: 10.1056/NEJMoa1805689.
   PubMed Web of Science ®Google Scholar
• Damy T, Garcia-Pavia P, Hanna M, et al. Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23(2):277–285. doi: 10.1002/ejhf.2027.
   PubMed Web of Science ®Google Scholar
• Warner AL. Advances in the treatment of transthyretin cardiac amyloidosis: current and emerging therapies. Pharmacotherapy. 2021;41(12):1081–1091. doi: 10.1002/phar.2639.
   PubMed Web of Science ®Google Scholar
• Khedraki R. Cardiac amyloidosis: an update on diagnosis, current therapy, and future directions. Curr Opin Cardiol. 2022;37(3):272–284. doi: 10.1097/HCO.0000000000000953.
   PubMed Web of Science ®Google Scholar
• Plumadore E, Lombardo L, Cabral KP. Pharmacotherapy review: emerging treatment modalities in transthyretin cardiac amyloidosis. Am J Health Syst Pharm. 2022;79(2):52–62. doi: 10.1093/ajhp/zxab356.
   PubMed Web of Science ®Google Scholar
• Kammerlander AA, Marzluf BA, Zotter-Tufaro C, et al. T1 mapping by CMR imaging: from histological validation to clinical implication. JACC Cardiovasc Imaging. 2016;9(1):14–23. doi: 10.1016/j.jcmg.2015.11.002.
   PubMed Web of Science ®Google Scholar
• Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122(2):138–144. doi: 10.1161/CIRCULATIONAHA.109.930636.
   PubMed Web of Science ®Google Scholar
• Mascherbauer J, Marzluf BA, Tufaro C, et al. Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging. 2013;6(6):1056–1065. doi: 10.1161/CIRCIMAGING.113.000633.
   PubMed Web of Science ®Google Scholar
• Aus Dem Siepen F, Buss SJ, Messroghli D, et al. T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy. Eur Heart J Cardiovasc Imaging. 2015;16(2):210–216. doi: 10.1093/ehjci/jeu183.
   PubMed Web of Science ®Google Scholar
• Bull S, White SK, Piechnik SK, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99(13):932–937. doi: 10.1136/heartjnl-2012-303052.
   PubMed Web of Science ®Google Scholar
• Fontana M, White SK, Banypersad SM, et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson. 2012;14(1):88. doi: 10.1186/1532-429X-14-88.
   PubMedGoogle Scholar
• Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52(19):1574–1580. doi: 10.1016/j.jacc.2008.06.049.
   PubMed Web of Science ®Google Scholar
• Iles LM, Ellims AH, Llewellyn H, et al. Histological validation of cardiac magnetic resonance analysis of regional and diffuse interstitial myocardial fibrosis. Eur Heart J Cardiovasc Imaging. 2015;16(1):14–22. doi: 10.1093/ehjci/jeu182.
   PubMed Web of Science ®Google Scholar
• Miller CA, Naish JH, Bishop P, et al. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging. 2013;6(3):373–383. doi: 10.1161/CIRCIMAGING.112.000192.
   PubMed Web of Science ®Google Scholar
• White SK, Sado DM, Fontana M, et al. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging. 2013;6(9):955–962. doi: 10.1016/j.jcmg.2013.01.011.
   PubMed Web of Science ®Google Scholar
• Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70(4):466–477. doi: 10.1016/j.jacc.2017.05.053.
   PubMed Web of Science ®Google Scholar
• Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2019;12(5):810–819. doi: 10.1016/j.jcmg.2018.02.006.
   PubMed Web of Science ®Google Scholar
• Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076–1084. doi: 10.1016/j.jacc.2005.05.073.
   PubMed Web of Science ®Google Scholar
• Arheden H, Saeed M, Higgins CB, et al. Measurement of the distribution volume of gadopentetate dimeglumine at echo-planar MR imaging to quantify myocardial infarction: comparison with 99mTc-DTPA autoradiography in rats. Radiology. 1999;211(3):698–708. doi: 10.1148/radiology.211.3.r99jn41698.
   PubMed Web of Science ®Google Scholar
• Chen W, Doeblin P, Al-Tabatabaee S, et al. Synthetic extracellular volume in cardiac magnetic resonance without blood sampling: a reliable tool to replace conventional extracellular volume. Circ Cardiovasc Imaging. 2022;15(4):e013745.
   PubMed Web of Science ®Google Scholar
• Schönland SO, Hegenbart U, Bochtler T, et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood. 2012;119(2):488–493. doi: 10.1182/blood-2011-06-358507.
   PubMed Web of Science ®Google Scholar
• Hahn K, Nilsson KPR, Hammarström P, et al. Establishing and validating the fluorescent amyloid ligand h-FTAA (heptamer formyl thiophene acetic acid) to identify transthyretin amyloid deposits in carpal tunnel syndrome. Amyloid. 2017;24(2):78–86. doi: 10.1080/13506129.2017.1316711.
   PubMed Web of Science ®Google Scholar
• Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging. 2020;13(6):1368–1383. doi: 10.1016/j.jcmg.2019.07.015.
   PubMed Web of Science ®Google Scholar
• Dorbala S, Kijewski MF, Park MA. Quantitative bone-avid tracer SPECT/CT for cardiac amyloidosis: a crucial step forward. JACC Cardiovasc Imaging. 2020;13(6):1364–1367. doi: 10.1016/j.jcmg.2020.05.005.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Guidalotti PL, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging. 2011;4(6):659–670. doi: 10.1016/j.jcmg.2011.03.016.
   PubMed Web of Science ®Google Scholar
• Singh V, Falk R, Di Carli MF, et al. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol. 2019;26(1):158–173. doi: 10.1007/s12350-018-01552-4.
   PubMed Web of Science ®Google Scholar
• Ross JC, Hutt DF, Burniston M, et al. Quantitation of (99m)Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid. 2018;25(3):203–210. doi: 10.1080/13506129.2018.1520087.
   PubMed Web of Science ®Google Scholar
• Ben-Haim S, Chicheportiche A, Goshen E, et al. Quantitative SPECT/CT parameters of myocardial (99m)technetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis. EJNMMI Res. 2021;11(1):86. doi: 10.1186/s13550-021-00828-0.
   PubMed Web of Science ®Google Scholar
• Löfbacka V, Axelsson J, Pilebro B, et al. Cardiac transthyretin amyloidosis (99m)Tc-DPD SPECT correlates with strain echocardiography and biomarkers. Eur J Nucl Med Mol Imaging. 2021;48(6):1822–1832. doi: 10.1007/s00259-020-05144-8.
   PubMed Web of Science ®Google Scholar
• Morioka M, Takashio S, Nakashima N, et al. Correlation between cardiac images, biomarkers, and amyloid load in wild-type transthyretin amyloid cardiomyopathy. J Am Heart Assoc. 2022;11(12):e024717.
   PubMed Web of Science ®Google Scholar
• Kristen AV, Brokbals E, Aus Dem Siepen F, et al. Cardiac amyloid load: a prognostic and predictive biomarker in patients with light-chain amyloidosis. J Am Coll Cardiol. 2016;68(1):13–24. doi: 10.1016/j.jacc.2016.04.035.
   PubMed Web of Science ®Google Scholar
• Hutt DF, Fontana M, Burniston M, et al. Prognostic utility of the perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18(12):1344–1350. doi: 10.1093/ehjci/jew325.
   PubMed Web of Science ®Google Scholar
• Kristen AV, Scherer K, Buss S, et al. Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(5):502–510. doi: 10.1016/j.jcmg.2014.03.002.
   PubMed Web of Science ®Google Scholar
• Miller RJH, Cadet S, Mah D, et al. Diagnostic and prognostic value of technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. J Nucl Cardiol. 2021;28(5):1835–1845. doi: 10.1007/s12350-021-02563-4.
   PubMed Web of Science ®Google Scholar
• Roshankar G, White GC, Cadet S, et al. Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis. J Nucl Cardiol. 2022;29(5):2679–2690. doi: 10.1007/s12350-021-02806-4.
   PubMed Web of Science ®Google Scholar
• Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression. JACC Cardiovasc Imaging. 2021;14(1):189–199. doi: 10.1016/j.jcmg.2020.07.043.
   PubMed Web of Science ®Google Scholar
• Ross JC, Hutt DF, Burniston M, et al. The role of serial (99m)Tc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis. Amyloid. 2022;29(1):38–49. doi: 10.1080/13506129.2021.1991302.
   PubMed Web of Science ®Google Scholar
• Stats MA, Stone JR. Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis. Cardiovasc Pathol. 2016;25(5):413–417. doi: 10.1016/j.carpath.2016.07.001.
   PubMed Web of Science ®Google Scholar
• Thelander U, Westermark GT, Antoni G, et al. Cardiac microcalcifications in transthyretin (ATTR) amyloidosis. Int J Cardiol. 2022;352:84–91. doi: 10.1016/j.ijcard.2022.01.036.
   PubMed Web of Science ®Google Scholar
• Pomerance A, Slavin G, McWatt J. Experience with the sodium sulphate-Alcian blue stain for amyloid in cardiac pathology. J Clin Pathol. 1976;29(1):22–26. doi: 10.1136/jcp.29.1.22.
   PubMed Web of Science ®Google Scholar